Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Prostate Cancer

  Free Subscription


Articles published in BJU Int

Retrieve available abstracts of 356 articles:
HTML format



Single Articles


    June 2020
  1. MATTI B, Lyndon M, Zargar-Shoshtari K
    Ethnic and Socioeconomic disparities in Prostate Cancer Screening - Lessons from New Zealand.
    BJU Int. 2020 Jun 29. doi: 10.1111/bju.15155.
    PubMed     Abstract available


  2. CHEN MY, Franklin A, Yaxley J, Gianduzzo T, et al
    Solitary rib lesions showing PSMA uptake in pre-treatment staging (68) Ga-PSMA-11 PET scans for men with prostate cancer: benign or malignant?
    BJU Int. 2020 Jun 27. doi: 10.1111/bju.15152.
    PubMed     Abstract available


  3. ANTON A, Kamel Hasan O, Ballok Z, Bowden P, et al
    Use of PSMA PET/CT in Response Assessment Following Upfront Chemohormonal Therapy in Metastatic Prostate Cancer.
    BJU Int. 2020 Jun 24. doi: 10.1111/bju.15151.
    PubMed     Abstract available


  4. MAYOR N, Sathianathen NJ, Buteau J, Koschel S, et al
    PSMA Theranostics in advanced prostate cancer: an evolving option.
    BJU Int. 2020 Jun 19. doi: 10.1111/bju.15143.
    PubMed     Abstract available


  5. TOMER A, Nieboer D, Roobol MJ, Bjartell A, et al
    Personalized Biopsy Schedules Based on Risk of Gleason Upgrading for Low-Risk Prostate Cancer Active Surveillance Patients.
    BJU Int. 2020 Jun 12. doi: 10.1111/bju.15136.
    PubMed     Abstract available


  6. PFISTER D, Haidl F, Nestler T, Verburg F, et al
    (68) Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer.
    BJU Int. 2020 Jun 12. doi: 10.1111/bju.15135.
    PubMed     Abstract available


  7. FRANKLIN A, Yaxley WJ, Raveenthiran S, Coughlin G, et al
    Histological comparison between predictive value of pre-operative 3T multiparametric MRI and (68) Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
    BJU Int. 2020 Jun 10. doi: 10.1111/bju.15134.
    PubMed     Abstract available


  8. AKAKURA K, Bolton D, Grillo V, Mermod N, et al
    Not All Prostate Cancer is the Same - Patient perceptions: An Asia-Pacific study.
    BJU Int. 2020 Jun 10. doi: 10.1111/bju.15129.
    PubMed     Abstract available


  9. LANGLEY SEM
    Low-dose-rate brachytherapy for prostate cancer stands the test of time - the Swiss experience.
    BJU Int. 2020;125:750-751.
    PubMed    


    May 2020
  10. MARRA G, Zhuang J, Beltrami M, Calleris G, et al
    Transperineal free-hand mpMRI fusion targeted biopsies under local anesthesia for Prostate Cancer Diagnosis: a multicenter prospective study of 1,014 cases.
    BJU Int. 2020 May 26. doi: 10.1111/bju.15121.
    PubMed     Abstract available


  11. POPERT R, Kum F, MacAskill F, Stroman L, et al
    Our First Month of Delivering the Prostate Cancer Diagnostic Pathway within the Limitations of COVID-19 Using Local Anaesthetic Transperineal Biopsy.
    BJU Int. 2020 May 26. doi: 10.1111/bju.15120.
    PubMed     Abstract available


  12. WURNSCHIMMEL C, Maurer T, Knipper S, von Breunig F, et al
    Martini-Klinik experience on prostate cancer surgery during the early phase of COVID-19.
    BJU Int. 2020 May 18. doi: 10.1111/bju.15115.
    PubMed     Abstract available


  13. JOSHI A, Roberts MJ, Alinezhad S, Williams ED, et al
    Challenges, applications and future directions of precision medicine in prostate cancer - the role of organoids and patient-derived xenografts.
    BJU Int. 2020 May 8. doi: 10.1111/bju.15103.
    PubMed     Abstract available


  14. SCHWEN ZR, Mamawala M, Tosoian JJ, Druskin SC, et al
    Prostate Health Index and Multiparametric MRI to Predict Prostate Cancer Grade Reclassification in Active Surveillance.
    BJU Int. 2020 May 4. doi: 10.1111/bju.15101.
    PubMed     Abstract available


  15. SHAPIRO DD, Ward JF, Lim AH, Nogueras-Gonzalez GM, et al
    Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance.
    BJU Int. 2020 May 1. doi: 10.1111/bju.15100.
    PubMed     Abstract available


  16. HAEUSER L, Nguyen DD, Trinh QD
    Prostate cancer and kidney transplantation - exclusion or co-existence?
    BJU Int. 2020;125:628-629.
    PubMed    


  17. NABI J
    The provision of comfort: addressing barriers to sleep in prostate cancer.
    BJU Int. 2020;125:627-628.
    PubMed    


    April 2020
  18. SEYMOUR ZA, Hamstra DA, Daignault-Newton S, Bosch W, et al
    Long-term Follow-up After Radiotherapy for Prostate Cancer with and without Rectal Hydrogel Spacer: A Pooled Prospective Evaluation of Bowel Associated Quality of Life.
    BJU Int. 2020 Apr 25. doi: 10.1111/bju.15097.
    PubMed     Abstract available


  19. HEIDENREICH A, Bludau M, Bruns C, Nestler T, et al
    Pelvic exenteration surgery in patients with locally advanced castration-naive and castration-resistant, symptomatic prostate cancer.
    BJU Int. 2020 Apr 22. doi: 10.1111/bju.15088.
    PubMed     Abstract available


  20. NORRIS JM, Carmona Echeverria LM, Simpson BS, Allen C, et al
    Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: High Gleason Grade and Increased Tumour Volume are Not the Only Important Histopathological Features.
    BJU Int. 2020 Apr 22. doi: 10.1111/bju.15085.
    PubMed     Abstract available


  21. MANNAERTS CK, Engelbrecht MRW, Postema AW, van Kollenburg RAA, et al
    Detection of clinically significant prostate cancer in biopsy-naive men: Head-to-head comparison of systematic biopsy, multiparametric MRI- and contrast ultrasound dispersion imaging-targeted biopsy.
    BJU Int. 2020 Apr 21. doi: 10.1111/bju.15093.
    PubMed     Abstract available


  22. SZARVAS T, Csizmarik A, Fazekas T, Huttl A, et al
    Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
    BJU Int. 2020 Apr 20. doi: 10.1111/bju.15086.
    PubMed     Abstract available


  23. BORNO HT, Zhang S, Bakke B, Bell A, et al
    Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials.
    BJU Int. 2020 Apr 10. doi: 10.1111/bju.15081.
    PubMed     Abstract available


  24. ORRASON AW, Westerberg M, Garmo H, Franck Lissbrant I, et al
    Changes in treatment and mortality in men with locally advanced prostate cancer between 2000-2016. Nationwide, population-based study in Sweden.
    BJU Int. 2020 Apr 10. doi: 10.1111/bju.15077.
    PubMed     Abstract available


  25. ALBERTSEN PC
    Estimating the threat posed by prostate cancer.
    BJU Int. 2020;125:480-481.
    PubMed    


  26. STONIER T, Cathcart P
    Further evidence that surgery after focal therapy for prostate cancer is safe.
    BJU Int. 2020;125:481-482.
    PubMed    


    March 2020
  27. OSSES DF, Drost FH, Verbeek JFM, Luiting HB, et al
    Prostate cancer upgrading with serial prostate MRI scans and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?
    BJU Int. 2020 Mar 31. doi: 10.1111/bju.15065.
    PubMed     Abstract available


  28. HUITS TH, Luiting HB, van der Poel H, Nandurkar R, et al
    The distribution of prostate cancer recurrences on (68) Ga-PSMA PET/CT after radical prostatectomy with pathological node positive extended lymph node dissection.
    BJU Int. 2020 Mar 17. doi: 10.1111/bju.15052.
    PubMed     Abstract available


  29. RANASINGHE W, Chapin BF, Kim IY, Sooriakumaran P, et al
    The Cytoreductive prostatectomy in Metastatic Prostate Cancer: What the individual trials are hoping to answer.
    BJU Int. 2020 Mar 16. doi: 10.1111/bju.15055.
    PubMed     Abstract available


  30. LUZZAGO S, de Cobelli O, Cozzi G, Peveri G, et al
    A novel nomogram to identify candidates for active surveillance among patients with ISUP Grade Group 1 or ISUP Grade Group 2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
    BJU Int. 2020 Mar 9. doi: 10.1111/bju.15048.
    PubMed     Abstract available


  31. DONG L, Zhang Z, Smith K, Kuczler M, et al
    The combination of size-based separation and selection-free technology provides higher circulating tumor cells detection sensitivity than either method alone in patients with metastatic prostate cancer.
    BJU Int. 2020 Mar 1. doi: 10.1111/bju.15041.
    PubMed     Abstract available


    February 2020
  32. MORTEZAVI A, Eklund M, Bergman M, Kjosavik SR, et al
    Association between PSA density and prostate cancer in men without significant MRI lesions.
    BJU Int. 2020 Feb 28. doi: 10.1111/bju.15037.
    PubMed     Abstract available


  33. SOOD A, Keeley J, Palma-Zamora I, Dalela D, et al
    Extended pelvic lymph-node dissection is independently associated with improved overall survival in prostate cancer patients at high-risk for lymph-node invasion.
    BJU Int. 2020 Feb 11. doi: 10.1111/bju.15034.
    PubMed     Abstract available


  34. MAMAWALA MK, Meyer A, Landis P, Macura KJ, et al
    Utility of multiparametric MRI in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance.
    BJU Int. 2020 Feb 10. doi: 10.1111/bju.15033.
    PubMed     Abstract available


    January 2020
  35. LOVEGROVE CE, Peters M, Guillaumier S, Arya M, et al
    Evaluation of functional outcomes following a second focal-HIFU in men with primary localised, non-metastatic prostate cancer; Results from the High Intensity Focused Ultrasound Evaluation and Assessment of Treatment (HEAT) Registry.
    BJU Int. 2020 Jan 23. doi: 10.1111/bju.15004.
    PubMed     Abstract available


  36. VIKTORIN P, Putora PM, Schmid HP, Plasswilm L, et al
    Long-term oncological and functional follow-up in low dose rate brachytherapy (LDR-BT) for prostate cancer: results from the prospective nation-wide Swiss Registry.
    BJU Int. 2020 Jan 21. doi: 10.1111/bju.15003.
    PubMed     Abstract available


  37. AMIN A, Blazevski A, Thompson J, Scheltema MJ, et al
    PRIMARY Trial - A prospective multi-centre cross-sectional study of the additive diagnostic value of gallium-68 prostate specific membrane antigen (PSMA) PET/CT to multiparametric (mp) MRI in the diagnostic setting for men being investigated for prost
    BJU Int. 2020 Jan 19. doi: 10.1111/bju.14999.
    PubMed     Abstract available


  38. BRATT O, Drevin L, Prutz KG, Carlsson S, et al
    Prostate cancer in kidney transplant recipients- a nationwide register study.
    BJU Int. 2020 Jan 19. doi: 10.1111/bju.15002.
    PubMed     Abstract available


  39. LOVEGROVE CE, Musbahi O, Ranasinha N, Omer A, et al
    Implications of celebrity endorsement of prostate cancer awareness in a tertiary referral unit- The "Fry-Turnbull" Effect.
    BJU Int. 2020 Jan 7. doi: 10.1111/bju.14992.
    PubMed     Abstract available


  40. ROBBINS R, Jean-Louis G, Chanko N, Combs P, et al
    Using data from an online health community to examine the impact of prostate cancer on sleep.
    BJU Int. 2020 Jan 3. doi: 10.1111/bju.14986.
    PubMed     Abstract available


  41. JAMBOR I, Falagario U
    Does prostate magnetic resonance imaging (MRI) reporting system affect performance of MRI in men with a clinical suspicion of prostate cancer?
    BJU Int. 2020;125:4-5.
    PubMed    


    December 2019
  42. UEMURA H, Ye D, Kanesvaran R, Chiong E, et al
    United in Fight against prOstate cancer registry (UFO): first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia.
    BJU Int. 2019 Dec 23. doi: 10.1111/bju.14980.
    PubMed     Abstract available


    November 2019
  43. WOLLERSHEIM BM, Boekhout AH, van der Poel HG, van de Poll-Franse LV, et al
    The risk of developing cardiovascular disease is increased for prostate cancer patients who are pharmaceutically treated for depression.
    BJU Int. 2019 Nov 26. doi: 10.1111/bju.14961.
    PubMed     Abstract available


  44. CHINEGWUNDOH MBE F, Perera R
    Evaluating psychological support services available for men living with prostate cancer and their carers and families across England.
    BJU Int. 2019 Nov 26. doi: 10.1111/bju.14959.
    PubMed     Abstract available


  45. PULLEN L, Radtke JP, Wiesenfarth M, Roobol MJ, et al
    External validation of novel MRI-based models for prostate cancer prediction.
    BJU Int. 2019 Nov 23. doi: 10.1111/bju.14958.
    PubMed     Abstract available


  46. ELDRED-EVANS D, Neves JB, Simmons LAM, Kanthabalan A, et al
    The added value of diffusion-weighted images and dynamic contrast-enhancement in multi-parametric MRI for the detection of clinically significant prostate cancer in the PICTURE trial.
    BJU Int. 2019 Nov 16. doi: 10.1111/bju.14953.
    PubMed     Abstract available


  47. BLAZEVSKI A, Scheltema MJ, Amin A, Thompson J, et al
    Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment.
    BJU Int. 2019 Nov 14. doi: 10.1111/bju.14951.
    PubMed     Abstract available


  48. LANGLEY S, Uribe J, Uribe-Lewis S, Franklin A, et al
    Hemi-Ablative Low-Dose-Rate Prostate Brachytherapy for Unilateral Localised Prostate Cancer.
    BJU Int. 2019 Nov 9. doi: 10.1111/bju.14948.
    PubMed     Abstract available


  49. ZHOU SR, Priester AM, Jayadevan R, Johnson DC, et al
    Using Spatial Tracking with MRI/Ultrasound-Guided Biopsy to Identify Unilateral Prostate Cancer.
    BJU Int. 2019 Nov 4. doi: 10.1111/bju.14943.
    PubMed     Abstract available


  50. LUITING HB, van Leeuwen PJ, Busstra MB, Brabander T, et al
    Use of (68) Ga-PSMA PET for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    BJU Int. 2019 Nov 4. doi: 10.1111/bju.14944.
    PubMed     Abstract available


    October 2019
  51. THANGASAMY IA, Kwan EM, Teh J, Sathianathen N, et al
    Novel agents for metastatic hormone-sensitive prostate cancer - A practice guide for urologists.
    BJU Int. 2019 Oct 29. doi: 10.1111/bju.14936.
    PubMed     Abstract available


  52. KLOTZ L
    Active surveillance in intermediate risk prostate cancer.
    BJU Int. 2019 Oct 24. doi: 10.1111/bju.14935.
    PubMed     Abstract available


  53. HOFMAN MS, Emmett L, Violet J, Y Zhang A, et al
    TheraP: a randomized phase 2 trial of (177) Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).
    BJU Int. 2019 Oct 22. doi: 10.1111/bju.14876.
    PubMed     Abstract available


  54. MACIAS VA, Barrera-Mellado I
    Ultra-Hypofractionated Radiation Therapy for Unfavorable Intermediate-Risk and High-Risk Prostate Cancer is Safe and Effective: 5-year Outcomes of a Phase II Trial.
    BJU Int. 2019 Oct 15. doi: 10.1111/bju.14925.
    PubMed     Abstract available


  55. NDJAVERA W, Orange ST, O'Doherty AF, Leicht AS, et al
    Exercise-induced attenuation of treatment side-effects in newly diagnosed prostate cancer patients beginning androgen deprivation therapy: a randomised controlled trial.
    BJU Int. 2019 Oct 12. doi: 10.1111/bju.14922.
    PubMed     Abstract available


  56. NORRIS JM, Simpson BS, Parry MA, Kasivisvanathan V, et al
    Genetic correlates of prostate cancer visibility (and invisibility) on mpMRI: It's time to take stock.
    BJU Int. 2019 Oct 10. doi: 10.1111/bju.14919.
    PubMed     Abstract available


  57. KHOO CC, Eldred-Evans D, Peters M, Bertoncelli Tanaka M, et al
    Likert vs. PI-RADS v2: A Comparison of Two Radiological Scoring Systems for Detection of Clinically Significant Prostate Cancer.
    BJU Int. 2019 Oct 9. doi: 10.1111/bju.14916.
    PubMed     Abstract available


    September 2019
  58. GNANAPRAGASAM VJ
    Informing informed decision making in Primary Prostate Cancer treatment selection.
    BJU Int. 2019 Sep 12. doi: 10.1111/bju.14910.
    PubMed     Abstract available


  59. ONG WL, Koh TL, Lim Joon D, Chao M, et al
    Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literatur
    BJU Int. 2019 Sep 11. doi: 10.1111/bju.14886.
    PubMed     Abstract available


  60. ROBERTS MJ, Papa N, Perera M, Scott S, et al
    A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer.
    BJU Int. 2019 Sep 5. doi: 10.1111/bju.14773.
    PubMed     Abstract available


  61. COOK GJR, Kulkarni M, Warbey VS
    PSMA PET/CT imaging for primary staging of intermediate and high-risk prostate cancer.
    BJU Int. 2019;124:357-358.
    PubMed    


    August 2019
  62. SALTER CA, Mulhall JP
    Guideline of Guidelines: Testosterone Replacement Therapy for Testosterone Deficiency.
    BJU Int. 2019 Aug 17. doi: 10.1111/bju.14899.
    PubMed     Abstract available


  63. HOU Y, Bao ML, Wu CJ, Zhang J, et al
    A Machine Learning-assisted Decision Support Model Can Better Spare Extended Pelvic Lymph Node Dissection in Prostate Cancer.
    BJU Int. 2019 Aug 7. doi: 10.1111/bju.14892.
    PubMed     Abstract available


  64. SAKELLARIOU C, Elhage O, Papaevangelou E, Giustarini G, et al
    Prostate cancer cells enhance IL-15-mediated expansion of NK cells.
    BJU Int. 2019 Aug 7. doi: 10.1111/bju.14893.
    PubMed     Abstract available


  65. EMBERTON M
    Dropping the GAD - just a fad? The case for a simpler, quicker, safer and cheaper prostate magnetic resonance imaging.
    BJU Int. 2019;124:183-184.
    PubMed    


  66. FERRONI MC, Abaza R
    Feasibility of robot-assisted prostatectomy performed at ultra-low pneumoperitoneum pressure of 6 mmHg and comparison of clinical outcomes vs standard pressure of 15 mmHg.
    BJU Int. 2019;124:308-313.
    PubMed     Abstract available


    July 2019
  67. BENARD A, Duroux T, Robert G
    Cost-utility analysis of focal HIFU versus active surveillance for low- to intermediate-risk prostate cancer using a Markov multi-state Model.
    BJU Int. 2019 Jul 12. doi: 10.1111/bju.14867.
    PubMed     Abstract available


  68. SCHELTEMA MJ, Chang JI, Stricker PD, van Leeuwen PJ, et al
    Diagnostic accuracy of (68) Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of
    BJU Int. 2019 Jul 9. doi: 10.1111/bju.14794.
    PubMed     Abstract available


  69. MEYER AR, Rowe SP, Gorin MA
    Preoperative PSMA-targeted PET imaging: more than just a tool for prostate cancer staging?
    BJU Int. 2019;124:2-3.
    PubMed    


  70. DASGUPTA P, Davis J, Hughes S
    NICE guidelines on prostate cancer 2019.
    BJU Int. 2019;124:1.
    PubMed    


  71. WATSON RW, Taltsh O
    Transcriptomic signatures for tertiary pattern 5 in prostate cancer.
    BJU Int. 2019;124:4-5.
    PubMed    



  72. NICE Guidance - Prostate cancer: diagnosis and management: (c) NICE (2019) Prostate cancer: diagnosis and management.
    BJU Int. 2019;124:9-26.
    PubMed    


  73. KALAPARA AA, Nzenza T, Pan HY, Ballok Z, et al
    Detection and localisation of primary prostate cancer using (68) Ga-PSMA PET/CT compared with mpMRI and radical prostatectomy specimens.
    BJU Int. 2019 Jul 1. doi: 10.1111/bju.14858.
    PubMed     Abstract available


  74. MARTINI A, Wang J, Brown NM, Cumarasamy S, et al
    A transcriptomic signature of tertiary Gleason 5 predicts worse clinicopathological outcome.
    BJU Int. 2019;124:155-162.
    PubMed     Abstract available


  75. MARTINI A, Cumarasamy S, Haines KG III, Tewari AK, et al
    An updated approach to incremental nerve sparing for robot-assisted radical prostatectomy.
    BJU Int. 2019;124:103-108.
    PubMed     Abstract available


  76. FREEDLAND SJ, Branche BL, Howard LE, Hamilton RJ, et al
    Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.
    BJU Int. 2019;124:69-75.
    PubMed     Abstract available


    June 2019
  77. REZAEE ME, Goddard B, Sverrisson EF, Seigne JD, et al
    Dr. Google: Trends in Online Interest in Prostate Cancer Screening, Diagnosis and Treatment.
    BJU Int. 2019 Jun 17. doi: 10.1111/bju.14846.
    PubMed     Abstract available


  78. HAESE A, Knipper S, Isbarn H, Heinzer H, et al
    A comparative study of robot-assisted and open radical prostatectomy in 10 790 men treated by highly trained surgeons for both procedures.
    BJU Int. 2019;123:1031-1040.
    PubMed     Abstract available


  79. REYNOLDS HM, Williams S, Jackson P, Mitchell C, et al
    Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework.
    BJU Int. 2019;123:1020-1030.
    PubMed     Abstract available


    May 2019
  80. HOSTIOU T, Gelet A, Chapelon JY, Rouviere O, et al
    Salvage high-intensity focused ultrasound for locally recurrent prostate cancer after low-dose-rate brachytherapy: oncologic and functional outcomes.
    BJU Int. 2019 May 30. doi: 10.1111/bju.14838.
    PubMed     Abstract available


  81. MAZZONE E, Mistretta FA, Knipper S, Palumbo C, et al
    Long-Term Incidence of Secondary Bladder, Rectal Cancer in Patients Treated with Brachytherapy for Localized Prostate Cancer: A Large-Scale Population-Based Analysis.
    BJU Int. 2019 May 30. doi: 10.1111/bju.14841.
    PubMed     Abstract available


  82. YAXLEY JW, Raveenthiran S, Nouhaud FX, Samaratunga H, et al
    Risk of metastatic disease on (68) Ga-PSMA PET/CT scan for primary staging of 1253 men at the diagnosis of prostate cancer.
    BJU Int. 2019 May 29. doi: 10.1111/bju.14828.
    PubMed     Abstract available


  83. MURPHY DG, Hofman MS, Azad A, Violet J, et al
    Going nuclear - It is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team.
    BJU Int. 2019 May 24. doi: 10.1111/bju.14814.
    PubMed     Abstract available


  84. CONNELL SP, Hanna M, McCarthy F, Hurst R, et al
    A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients.
    BJU Int. 2019 May 20. doi: 10.1111/bju.14811.
    PubMed     Abstract available


  85. TONTTILA PP, Ahtikoski A, Kuisma M, Paakko E, et al
    Multiparametric magnetic resonance imaging prior to radical prostatectomy identifies intraductal and cribriform growth pattern of prostate cancer.
    BJU Int. 2019 May 18. doi: 10.1111/bju.14812.
    PubMed     Abstract available


  86. QU LG, Wardan H, Davis ID, Iddawela M, et al
    Circulating Estrogen Receptor Mutations and Splice Variants in Advanced Prostate Cancer.
    BJU Int. 2019 May 15. doi: 10.1111/bju.14797.
    PubMed     Abstract available


  87. SAAD M, Alip A, Lim J, Abdullah MM, et al
    Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference (APCCC) 2017.
    BJU Int. 2019 May 11. doi: 10.1111/bju.14807.
    PubMed     Abstract available


  88. GNANAPRAGASAM VJ, Barrett T, Thankapannair V, Thurtle D, et al
    Using prognosis to guide inclusion criteria, define standardized end-points and stratify follow up in active surveillance for prostate cancer.
    BJU Int. 2019 May 7. doi: 10.1111/bju.14800.
    PubMed     Abstract available


  89. REMMERS S, Verbeek JFM, Nieboer D, van der Kwast T, et al
    Predicting biochemical recurrence and prostate cancer specific mortality after radical prostatectomy: comparison of six prediction models in a cohort of screen and clinically detected prostate cancer patients.
    BJU Int. 2019 May 4. doi: 10.1111/bju.14790.
    PubMed     Abstract available


  90. FINE ND, LaPolla F, Epstein M, Loeb S, et al
    Genomic Classifiers for Treatment Selection in Newly Diagnosed Prostate Cancer.
    BJU Int. 2019 May 4. doi: 10.1111/bju.14799.
    PubMed     Abstract available


  91. DEL RE M, Crucitta S, Sbrana A, Rofi E, et al
    AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer.
    BJU Int. 2019 May 4. doi: 10.1111/bju.14792.
    PubMed     Abstract available


  92. HERLEMANN A, Meng MV
    Editorial: Conversion to negative surgical margin after intraoperative frozen section - (un)necessary effort and relevance in 2019?
    BJU Int. 2019;123:744-746.
    PubMed    


  93. AHN T, Roberts MJ, Strahan A, Malone G, et al
    Improved lower urinary tract symptoms after robot-assisted radical prostatectomy: implications for survivorship, treatment selection and patient counselling.
    BJU Int. 2019;123 Suppl 5:47-53.
    PubMed     Abstract available


  94. SEWELL J, Chow K, De Sousa A, Sapre N, et al
    Extended-spectrum beta-lactamase in the rectal flora of patients undergoing transrectal prostate biopsy: a study of the prevalence in a major metropolitan hospital.
    BJU Int. 2019;123 Suppl 5:43-46.
    PubMed     Abstract available


  95. SLUKA P, Pezaro C, Wardan H, Sengupta S, et al
    Identification of novel oncogenic events occurring early in prostate carcinogenesis using purified autologous malignant and non-malignant prostate epithelial cells.
    BJU Int. 2019;123 Suppl 5:27-35.
    PubMed     Abstract available


    April 2019
  96. RANASINGHE WKB, Williams S, Ischia J, Wetherell D, et al
    Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer.
    BJU Int. 2019 Apr 23. doi: 10.1111/bju.14709.
    PubMed     Abstract available


  97. VILLUMSEN BR, Jorgensen MG, Frystyk J, Hordam B, et al
    Home-based exergaming was safe and significantly improved 6-min walking distance in prostate cancer patients: a single-blinded randomized controlled trial.
    BJU Int. 2019 Apr 22. doi: 10.1111/bju.14782.
    PubMed     Abstract available


  98. REICHARD CA, Hoffman KE, Tang C, Williams SB, et al
    Radical Prostatectomy or Radiotherapy for High and Very High Risk Prostate Cancer: A Multidisciplinary Clinic Experience of Patients Eligible for Either Treatment.
    BJU Int. 2019 Apr 22. doi: 10.1111/bju.14780.
    PubMed     Abstract available


  99. SARGOS P, Mottet N, Bellera C, Richaud P, et al
    Long-term androgen deprivation, with or without radiotherapy, in locally-advanced prostate cancer: updated results from a phase III randomized trial.
    BJU Int. 2019 Apr 4. doi: 10.1111/bju.14768.
    PubMed     Abstract available


  100. VAN HEMELRIJCK M
    The burden of urological cancers in low- and middle-income countries.
    BJU Int. 2019;123:557.
    PubMed    


    March 2019
  101. ALABOUSI M, Salameh JP, Gusenbauer K, Samoilov L, et al
    Biparametric versus Multiparametric Prostate MRI for the Detection of Prostate Cancer in Treatment-Naive Patients: A Diagnostic Test Accuracy Systematic Review and Meta-Analysis.
    BJU Int. 2019 Mar 31. doi: 10.1111/bju.14759.
    PubMed     Abstract available


  102. SZYMANIAK JA, Mata DA, Cole AP
    Are historical studies relevant in the setting of grade migration?
    BJU Int. 2019;123:375-376.
    PubMed    


  103. PRESS B, Rosenkrantz AB, Huang R, Taneja SS, et al
    The ultrasound characteristics of regions identified as suspicious by magnetic resonance imaging (MRI) predict the likelihood of clinically significant cancer on MRI-ultrasound fusion-targeted biopsy.
    BJU Int. 2019;123:439-446.
    PubMed     Abstract available


  104. PORPIGLIA F, Manfredi M, Checcucci E, Garrou D, et al
    Use of chitosan membranes after nerve-sparing radical prostatectomy improves early recovery of sexual potency: results of a comparative study.
    BJU Int. 2019;123:465-473.
    PubMed     Abstract available


  105. GALLAGHER KM, Christopher E, Cameron AJ, Little S, et al
    Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies.
    BJU Int. 2019;123:429-438.
    PubMed     Abstract available


    February 2019
  106. KE Y, Taylor J, Gao LL, Wang H, et al
    Twitter Response to the 2018 United States Preventive Services Task Force Guidelines on Prostate Cancer Screening.
    BJU Int. 2019 Feb 27. doi: 10.1111/bju.14734.
    PubMed     Abstract available


  107. LOPCI E, Piccardo A, Lazzeri M
    Prostate cancer imaging and therapeutic alternatives with highly specific molecular "probes".
    BJU Int. 2019 Feb 20. doi: 10.1111/bju.14713.
    PubMed     Abstract available


  108. SATHIANATHEN NJ, Philippou YA, Kuntz GM, Konety BR, et al
    Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer: A Cochrane Review.
    BJU Int. 2019 Feb 14. doi: 10.1111/bju.14711.
    PubMed     Abstract available


  109. STABILE A, Orczyk C, Hosking-Jervis F, Giganti F, et al
    Medium term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using HIFU for primary localized prostate cancer.
    BJU Int. 2019 Feb 12. doi: 10.1111/bju.14710.
    PubMed     Abstract available


  110. MERRIEL SWD, Hetherington L, Seggie A, Castle JT, et al
    Best practice in Active Surveillance for men with prostate cancer: A Prostate Cancer UK consensus statement.
    BJU Int. 2019 Feb 11. doi: 10.1111/bju.14707.
    PubMed     Abstract available


  111. GLASS AS, Dall'Era MA
    Use of Multi-Parametric Magnetic Resonance Imaging in Prostate Cancer Active Surveillance.
    BJU Int. 2019 Feb 11. doi: 10.1111/bju.14705.
    PubMed     Abstract available


  112. LIGHT A, Elhage O, Marconi L, Dasgupta P, et al
    Prostate cancer screening: where are we now?
    BJU Int. 2019 Feb 5. doi: 10.1111/bju.14692.
    PubMed     Abstract available


  113. KAM J, Yuminaga Y, Krelle M, Gavin D, et al
    How accurate is multi-parametric MRI for predicting prostate cancer pathology and tumour staging in the real world? - An Australian multi-centre study.
    BJU Int. 2019 Feb 3. doi: 10.1111/bju.14696.
    PubMed     Abstract available


  114. KRIMPHOVE MJ, Fletcher SA, Trinh QD
    Multiparametric magnetic resonance imaging for prostate cancer detection: do clinical trial findings reflect real-world practice?
    BJU Int. 2019;123:197-198.
    PubMed    


  115. ROSE BS
    Postoperative radiation and hormonal therapy for men with node-positive prostate cancer: a new standard?
    BJU Int. 2019;123:199-200.
    PubMed    


  116. TAAFFE DR, Galvao DA, Spry N, Joseph D, et al
    Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
    BJU Int. 2019;123:261-269.
    PubMed     Abstract available


  117. KINNEAR N, O'Callaghan M, Hennessey D, Liddell H, et al
    Intra-operative cell salvage in urological surgery: a systematic review and meta-analysis of comparative studies.
    BJU Int. 2019;123:210-219.
    PubMed     Abstract available


  118. GUPTA M, Patel HD, Schwen ZR, Tran PT, et al
    Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit.
    BJU Int. 2019;123:252-260.
    PubMed     Abstract available


    January 2019
  119. SIMOPOULOS DN, Sisk AE Jr, Priester A, Felker ER, et al
    Cancer Core Length from Targeted Biopsy: An Index of Prostate Cancer Volume and Pathologic Stage.
    BJU Int. 2019 Jan 29. doi: 10.1111/bju.14691.
    PubMed     Abstract available


  120. ANING JJ, Reilly GS, Fowler S, Challacombe B, et al
    Peri-operative and oncological outcomes of radical prostatectomy for high-risk prostate cancer in the UK: an analysis of surgeon reported data.
    BJU Int. 2019 Jan 25. doi: 10.1111/bju.14687.
    PubMed     Abstract available


  121. SIGHINOLFI MC, Sandri M, Torricelli P, Ligabue G, et al
    External validation of a novel side-specific, multiparametric magnetic resonance imaging-based nomogram for the prediction of extracapsular extension of prostate cancer: preliminary outcomes on a series diagnosed with mpMRI targeted plus systematic sa
    BJU Int. 2019 Jan 18. doi: 10.1111/bju.14665.
    PubMed     Abstract available


  122. REICHARD CA, Nyame YA, Sundi D, Tosoian J, et al
    Does time from diagnosis to treatment of high or very high risk prostate cancer affect outcome?
    BJU Int. 2019 Jan 17. doi: 10.1111/bju.14671.
    PubMed     Abstract available


  123. MA WK, Poon DM, Chan CK, Chan TW, et al
    Consensus statements on the management of clinically localised prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.
    BJU Int. 2019 Jan 17. doi: 10.1111/bju.14681.
    PubMed     Abstract available


  124. ROBINSON D, Garmo H, Van Hemelrijck M, Damber JE, et al
    Androgen deprivation therapy for prostate cancer and risk of dementia.
    BJU Int. 2019 Jan 13. doi: 10.1111/bju.14666.
    PubMed     Abstract available


  125. OMLIN A, Gillessen S
    The Advanced Prostate Cancer Consensus on a regional level - what can we learn?
    BJU Int. 2019;123:3-4.
    PubMed    


  126. WONG NC, Lam C, Patterson L, Shayegan B, et al
    Use of machine learning to predict early biochemical recurrence after robot-assisted prostatectomy.
    BJU Int. 2019;123:51-57.
    PubMed     Abstract available


  127. STONIER T, Simson N, Davis J, Challacombe B, et al
    Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) vs standard RARP: it's time for critical appraisal.
    BJU Int. 2019;123:5-7.
    PubMed    


  128. DESAI M, Bidair M, Bhojani N, Trainer A, et al
    WATER II (80-150 mL) procedural outcomes.
    BJU Int. 2019;123:106-112.
    PubMed     Abstract available


    December 2018
  129. GUPTA N, Bivalacqua TJ, Han M, Gorin MA, et al
    Evaluating the Impact of Length of Time from Diagnosis to Surgery in Patients with Unfavorable Intermediate to Very High-Risk Clinically Localized Prostate Cancer.
    BJU Int. 2018 Dec 20. doi: 10.1111/bju.14659.
    PubMed     Abstract available


  130. YANG YJ, Kong YY, Li GX, Wang Y, et al
    Phenotypes of Circulating Tumor Cells Predict Time to Castration Resistance in Metastatic Castration-Sensitive Prostate Cancer.
    BJU Int. 2018 Dec 7. doi: 10.1111/bju.14642.
    PubMed     Abstract available


  131. ROCCO B, Sighinolfi MC, Sandri M, Puliatti S, et al
    A novel nomogram for predicting ECE of prostate cancer.
    BJU Int. 2018;122:916-918.
    PubMed    


    November 2018
  132. GNANAPRAGASAM V, Barrett T, Massie C, Pacey S, et al
    Using prognosis to guide early detection and treatment selection in non-metastatic prostate cancer.
    BJU Int. 2018 Nov 30. doi: 10.1111/bju.14637.
    PubMed     Abstract available


  133. CHANDRASEKAR T, Dall'Era MA, Tilki D
    Multiparametric MRI: an important tool to improve risk stratification for active surveillance in prostate cancer.
    BJU Int. 2018;122:721-722.
    PubMed    


    October 2018
  134. ORCZYK C, Villers A, Rusinek H, Lepennec V, et al
    Prostate cancer heterogeneity: texture analysis score based on multiple MRI sequences for detection, stratification and selection of lesions at time of biopsy.
    BJU Int. 2018 Oct 30. doi: 10.1111/bju.14603.
    PubMed     Abstract available


  135. COLLINS A, Sundararajan V, Millar J, Burchell J, et al
    The trajectory of people who die from metastatic prostate cancer: A population-based study.
    BJU Int. 2018 Oct 29. doi: 10.1111/bju.14593.
    PubMed     Abstract available


  136. ONG WL, Yaxley JW, Millar JL
    Brachytherapy-based radiotherapy with androgen deprivation for management of high-risk prostate cancer - time to reverse the declining trend?
    BJU Int. 2018 Oct 19. doi: 10.1111/bju.14487.
    PubMed    


  137. VARMA M, Cochlin D, Delahunt B, Kynaston H, et al
    TNM clinical staging of prostate cancer: Issues and solutions.
    BJU Int. 2018 Oct 13. doi: 10.1111/bju.14589.
    PubMed     Abstract available


  138. GIELCHINSKY I, Chang J, Cusick T, Delprado W, et al
    Prostate Cancer in 432 men under the age of 50 years in the Prostate Specific Antigen era - a new outlook.
    BJU Int. 2018 Oct 10. doi: 10.1111/bju.14586.
    PubMed     Abstract available


  139. PINSKY PF, Miller E, Prorok P, Grubb R, et al
    Extended follow-up for prostate cancer incidence and mortality in the PLCO randomized cancer screening trial.
    BJU Int. 2018 Oct 5. doi: 10.1111/bju.14580.
    PubMed     Abstract available


  140. WARNER EW, Yip SM, Chi KN, Wyatt AW, et al
    DNA repair defects in prostate cancer: impact for screening, prognostication and treatment.
    BJU Int. 2018 Oct 3. doi: 10.1111/bju.14576.
    PubMed     Abstract available


  141. TORRES-ROMAN JS, Ruiz EF, Martinez-Herrera JF, Mendes Braga SF, et al
    Prostate Cancer Mortality rates in Peru and its geographic regions.
    BJU Int. 2018 Oct 3. doi: 10.1111/bju.14578.
    PubMed     Abstract available


    September 2018
  142. CAZZANIGA W, Garmo H, Robinson D, Holmberg L, et al
    Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study.
    BJU Int. 2018 Sep 25. doi: 10.1111/bju.14563.
    PubMed     Abstract available


  143. KAYE DR, Qi J, Morgan TM, Linsell S, et al
    Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.
    BJU Int. 2018 Sep 24. doi: 10.1111/bju.14554.
    PubMed     Abstract available


  144. VAN NIEUWENHOVE S, Saussez TP, Thiry S, Trefois P, et al
    Prospective comparison of a fast 1.5T biparametric to the 3.0T multi-parametric ESUR magnetic resonance imaging protocol as triage test for men at risk of prostate cancer.
    BJU Int. 2018 Sep 21. doi: 10.1111/bju.14538.
    PubMed     Abstract available


  145. STEUBER T, Tennstedt P, Macagno A, Athanasiou A, et al
    Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unneeded prostate biopsies.
    BJU Int. 2018 Sep 14. doi: 10.1111/bju.14540.
    PubMed     Abstract available


  146. VAN ROMPAY MI, Nickel JC, Ranganathan G, Kantoff PW, et al
    Impact of 5alpha-Reductase Inhibitors and alpha-Blockers for Benign Prostatic Hyperplasia on Prostate Cancer Incidence and Mortality.
    BJU Int. 2018 Sep 14. doi: 10.1111/bju.14534.
    PubMed     Abstract available


  147. JAMES ND
    Prognostic and predictive models in hormone-sensitive prostate cancer.
    BJU Int. 2018;122:352-353.
    PubMed    


  148. HUGHES SR
    2018: A Spacer Odyssey.
    BJU Int. 2018;122:353-354.
    PubMed    


  149. OXLEY J, Bray A, Rowe E
    Could a Mohs technique make NeuroSAFE a viable option?
    BJU Int. 2018;122:358-359.
    PubMed    


  150. CHANG KD, Abdel Raheem A, Choi YD, Chung BH, et al
    Retzius-sparing robot-assisted radical prostatectomy using the Revo-i robotic surgical system: surgical technique and results of the first human trial.
    BJU Int. 2018;122:441-448.
    PubMed     Abstract available


  151. KAOUK JH, Sagalovich D, Garisto J
    Robot-assisted transvesical partial prostatectomy using a purpose-built single-port robotic system.
    BJU Int. 2018;122:520-524.
    PubMed     Abstract available


  152. CHANDAK P, Byrne N, Lynch H, Allen C, et al
    Three-dimensional printing in robot-assisted radical prostatectomy - an Idea, Development, Exploration, Assessment, Long-term follow-up (IDEAL) Phase 2a study.
    BJU Int. 2018;122:360-361.
    PubMed    


  153. KADONO Y, Nohara T, Kawaguchi S, Naito R, et al
    Investigating the mechanism underlying urinary continence recovery after radical prostatectomy: effectiveness of a longer urethral stump to prevent urinary incontinence.
    BJU Int. 2018;122:456-462.
    PubMed     Abstract available


    August 2018
  154. WISSING M, Brimo F, Chevalier S, Scarlata E, et al
    Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer.
    BJU Int. 2018 Aug 16. doi: 10.1111/bju.14512.
    PubMed     Abstract available


  155. SHAH PH, Patel VR, Moreira DM, George AK, et al
    Implementation of Multiparametric Magnetic Resonance Imaging Technology for Evaluation of Patients with Suspicion for Prostate Cancer in the Clinical Practice Setting.
    BJU Int. 2018 Aug 16. doi: 10.1111/bju.14515.
    PubMed     Abstract available


  156. JUNG JH, Risk MC, Goldfarb R, Reddy B, et al
    Primary cryotherapy for localised or locally advanced prostate cancer.
    BJU Int. 2018 Aug 16. doi: 10.1111/bju.14519.
    PubMed     Abstract available


  157. FENIOUX C, Louvet C, Charton E, Rozet F, et al
    Switch from Abiraterone + Prednisone to Abiraterone + Dexamethasone at asymptomatic PSA progression in metastatic castration-resistant prostate cancer (mCRPC) patients.
    BJU Int. 2018 Aug 11. doi: 10.1111/bju.14511.
    PubMed     Abstract available


  158. CARLES J, Pichler A, Korunkova H, Tomova A, et al
    Observational, multicenter study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
    BJU Int. 2018 Aug 11. doi: 10.1111/bju.14509.
    PubMed     Abstract available


  159. VAN LEEUWEN PJ, Donswijk M, Nandurkar R, Stricker P, et al
    68Ga PSMA PET/CT predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate and high-risk prostate cancer.
    BJU Int. 2018 Aug 3. doi: 10.1111/bju.14506.
    PubMed     Abstract available



  160. NICE Advice - Prolaris gene expression assay for assessing long-term risk of prostate cancer progression: (c) NICE (2016) Prolaris gene expression assay for assessing long-term risk of prostate cancer progression.
    BJU Int. 2018;122:173-180.
    PubMed    


  161. CULIG Z
    The way towards understanding possible multiple functions of AR V7 in prostate cancer.
    BJU Int. 2018;122:169.
    PubMed    


  162. THOMPSON JE, Stricker PD
    MRI improves active surveillance of prostate cancer however biopsy is still crucial.
    BJU Int. 2018;122:E1-E2.
    PubMed    



  163. Abstracts of the 19th Asia-Pacific Prostate Cancer Conference 2018, 22 - 25 August 2018, Brisbane, Australia.
    BJU Int. 2018;122 Suppl 2:23-38.
    PubMed    


  164. CACCIAMANI G, Medina L, Ashrafi A, Landsberger H, et al
    Transvesical robot-assisted simple prostatectomy with 360 degrees circumferential reconstruction: step-by-step technique.
    BJU Int. 2018;122:344-348.
    PubMed     Abstract available


  165. MAXEINER A, Kittner B, Blobel C, Wiemer L, et al
    Primary magnetic resonance imaging/ultrasonography fusion-guided biopsy of the prostate.
    BJU Int. 2018;122:211-218.
    PubMed     Abstract available


  166. KNAAPILA J, Kallio H, Hakanen AJ, Syvanen K, et al
    Antibiotic susceptibility of intestinal Escherichia coli in men undergoing transrectal prostate biopsies: a prospective, registered, multicentre study.
    BJU Int. 2018;122:203-210.
    PubMed     Abstract available


  167. HUYNH LM, Osann K, Skarecky D, Ahlering TE, et al
    Predictive modelling of 2-year potency outcomes using a novel 90-day erection fullness scale after robot-assisted radical prostatectomy.
    BJU Int. 2018;122:249-254.
    PubMed     Abstract available


    July 2018
  168. SCAILTEUX LM, Rioux-Leclercq N, Vincendeau S, Balusson F, et al
    Use of 5alpha-reductase inhibitors for benign prostate hypertrophy and risk of high-grade prostate cancer: A French population-based study.
    BJU Int. 2018 Jul 19. doi: 10.1111/bju.14495.
    PubMed     Abstract available


  169. CHIONG E, Murphy DG, Akaza H, Buchan NC, et al
    Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference APCCC 2017.
    BJU Int. 2018 Jul 18. doi: 10.1111/bju.14489.
    PubMed     Abstract available


  170. PAK S, Park S, Kim M, Go H, et al
    The impact on oncologic outcomes after radical prostatectomy for prostate cancer of converting soft tissue margins at the apex and bladder neck from tumor positive to negative.
    BJU Int. 2018 Jul 6. doi: 10.1111/bju.14480.
    PubMed     Abstract available


  171. DAHRAN N, Szewczyk-Bieda M, Vinnicombe S, Fleming S, et al
    Periprostatic Fat Adipokines Expression Correlated with Prostate Cancer Aggressiveness in Men Undergoing Radical Prostatectomy for Clinically Localised Disease.
    BJU Int. 2018 Jul 3. doi: 10.1111/bju.14469.
    PubMed     Abstract available


  172. POPERT R
    Systematic transperineal and magnetic resonance imaging-targeted biopsies: the resolution of uncertainty.
    BJU Int. 2018;122:6-7.
    PubMed    


  173. LAVIANA AA, Penson DF
    Multiparametric magnetic resonance imaging (MRI) with targeted fusion biopsy: is the time now?
    BJU Int. 2018;122:1-2.
    PubMed    


  174. DE NUNZIO C, Lombardo R, Nacchia A, Tema G, et al
    Repeat prostate-specific antigen (PSA) test before prostate biopsy: a 20% decrease in PSA values is associated with a reduced risk of cancer and particularly of high-grade cancer.
    BJU Int. 2018;122:83-88.
    PubMed     Abstract available


    June 2018
  175. STONE NN, Stock RG
    Stage T3b prostate cancer diagnosed with seminal vesicle biopsy and treated by neoadjuvant hormone therapy, permanent brachytherapy and external beam irradiation.
    BJU Int. 2018 Jun 29. doi: 10.1111/bju.14464.
    PubMed     Abstract available


  176. ELLIOTT D, Hamdy FC, Leslie TA, Rosario D, et al
    Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation versus radical prostatectomy for unilateral localised prostate cancer.
    BJU Int. 2018 Jun 11. doi: 10.1111/bju.14432.
    PubMed     Abstract available


  177. KUANG AG, Nickel JC, Andriole GL, Castro-Santamaria R, et al
    Both acute and chronic inflammation are associated with lower perineural invasion in men with prostate cancer on repeat biopsy.
    BJU Int. 2018 Jun 6. doi: 10.1111/bju.14428.
    PubMed     Abstract available


  178. SOOD A, Abdollah F, Menon M
    Robot-assisted radical prostatectomy and a parachute.
    BJU Int. 2018;121:820-821.
    PubMed    


    May 2018
  179. OTTI VC, Miller C, Powell RJ, Thomas RM, et al
    The diagnostic accuracy of multiparametric MRI prior to biopsy in the detection of prostate cancer.
    BJU Int. 2018 May 27. doi: 10.1111/bju.14420.
    PubMed     Abstract available


  180. BANCROFT EK, Saya S, Page EC, Myhill K, et al
    The psychosocial impact of undergoing prostate cancer screening for men with BRCA1/2 mutations.
    BJU Int. 2018 May 26. doi: 10.1111/bju.14412.
    PubMed     Abstract available


  181. SZARVAS T, Sevcenco S, Modos O, Keresztes D, et al
    MMP-7, sFas and FasL serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.
    BJU Int. 2018 May 26. doi: 10.1111/bju.14415.
    PubMed     Abstract available


  182. KOVAC E, Vertosick EA, Sjoberg DD, Vickers AJ, et al
    Effects of Pathologic Upstaging or Upgrading on Metastasis and Cancer-Specific Mortality in men with Clinical Low-risk Prostate Cancer.
    BJU Int. 2018 May 26. doi: 10.1111/bju.14418.
    PubMed     Abstract available


  183. LOEB S, Taneja S, Walter D, Zweifach S, et al
    Crowd-Funding for Prostate Cancer and Breast Cancer.
    BJU Int. 2018 May 22. doi: 10.1111/bju.14408.
    PubMed     Abstract available


  184. ALI A, Hoyle A, Mistry H, Clarke NW, et al
    The importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer.
    BJU Int. 2018 May 19. doi: 10.1111/bju.14400.
    PubMed     Abstract available


  185. GANDAGLIA G, van den Bergh RCN, Tilki D, Fossati N, et al
    How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14391.
    PubMed     Abstract available


  186. ZHAO J, Sun G, Liao B, Zhang X, et al
    Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone-metastatic prostate cancer.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14398.
    PubMed     Abstract available


  187. ISHIOKA J, Matsuoka Y, Uehara S, Yasuda Y, et al
    Computer-aided diagnosis of prostate cancer on magnetic resonance imaging using a convolutional neural network algorithm.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14397.
    PubMed     Abstract available


  188. HAJILI T, Ohlmann CH, Linxweiler J, Niklas C, et al
    Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: Results of a single-institution series with long-term follow up.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14393.
    PubMed     Abstract available


  189. NEWTON RU, Jeffery E, Galvao DA, McIntyre C, et al
    Body composition, fatigue and exercise in patients with prostate cancer undergoing androgen deprivation therapy.
    BJU Int. 2018 May 11. doi: 10.1111/bju.14384.
    PubMed     Abstract available


  190. HOFMAN MS, Murphy DG, Williams SG, Nzenza T, et al
    A prospective randomised multi-centre study of the impact of Ga-68 PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    BJU Int. 2018 May 3. doi: 10.1111/bju.14374.
    PubMed     Abstract available


  191. EMBERTON M
    Has tailored, tissue-selective tumour ablation in men with prostate cancer come of age?
    BJU Int. 2018;121:676-677.
    PubMed    


  192. VENTIMIGLIA E, Briganti A, Montorsi F
    Lymph node dissection during radical prostatectomy for prostate cancer: extending the template in the right patients without increasing complications.
    BJU Int. 2018;121:677-678.
    PubMed    


  193. REYNOLDS BR, Bulsara C, Zeps N, Codde J, et al
    Exploring pathways towards improving patient experience of robot-assisted radical prostatectomy (RARP): assessing patient satisfaction and attitudes.
    BJU Int. 2018;121 Suppl 3:33-39.
    PubMed     Abstract available


  194. MISCHINGER J, Kaufmann S, Russo GI, Harland N, et al
    Targeted vs systematic robot-assisted transperineal magnetic resonance imaging-transrectal ultrasonography fusion prostate biopsy.
    BJU Int. 2018;121:791-798.
    PubMed     Abstract available


  195. MADERTHANER L, Furrer MA, Studer UE, Burkhard FC, et al
    More extended lymph node dissection template at radical prostatectomy detects metastases in the common iliac region and in the fossa of Marcille.
    BJU Int. 2018;121:725-731.
    PubMed     Abstract available


    April 2018
  196. BRIZMOHUN APPAYYA M, Adshead J, Ahmed HU, Allen C, et al
    National Implementation of multi-parametric MRI for prostate cancer detection - Recommendations from a UK consensus meeting.
    BJU Int. 2018 Apr 26. doi: 10.1111/bju.14361.
    PubMed     Abstract available


  197. SCHOOTS IG, Nieboer D, Giganti F, Moore CM, et al
    Is MRI-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis.
    BJU Int. 2018 Apr 21. doi: 10.1111/bju.14358.
    PubMed     Abstract available


  198. MARTINI A, Gupta A, Lewis SC, Cumarasamy S, et al
    Development and Internal Validation of a Side Specific, Multiparametric MRI-based Nomogram for the Prediction of Extracapsular Extension of Prostate Cancer.
    BJU Int. 2018 Apr 19. doi: 10.1111/bju.14353.
    PubMed     Abstract available


  199. BRYANT RJ, Yang B, Philippou Y, Lam K, et al
    Does the introduction of prostate multiparametric MRI into active surveillance of localised prostate cancer improve patient re-classification?
    BJU Int. 2018 Apr 12. doi: 10.1111/bju.14248.
    PubMed     Abstract available


  200. CASH H, Steiner U, Heidenreich A, Klotz T, et al
    Intermittent docetaxel therapy versus continuous docetaxel therapy in patients with castration resistant prostate cancer (CRPC) - a phase III study (PRINCE).
    BJU Int. 2018 Apr 10. doi: 10.1111/bju.14239.
    PubMed     Abstract available


  201. LANCEE M, Tikkinen KAO, de Reijke TM, Kataja VV, et al
    Guideline of guidelines: primary monotherapies for localised or locally advanced prostate cancer.
    BJU Int. 2018 Apr 7. doi: 10.1111/bju.14237.
    PubMed     Abstract available


  202. EBBINGE M, Berglund A, Varenhorst E, Hedlund PO, et al
    Clinical and Prognostic Significance of Changes in Haemoglobin Level During One Year of Androgen Deprivation Treatment for Hormone-Naive Bone Metastatic Prostate Cancer.
    BJU Int. 2018 Apr 2. doi: 10.1111/bju.14227.
    PubMed     Abstract available


  203. HARMOUCH SS, Berger AJ, Cole AP
    Low rates of bone density testing in prostate cancer survivors on androgen-deprivation therapy: where do we go from here?
    BJU Int. 2018;121:492-493.
    PubMed    


  204. KLOTZ L
    Prostate cancer prevention: proof is elusive.
    BJU Int. 2018;121:487-488.
    PubMed    


  205. LAING R, Uribe J, Uribe-Lewis S, Money-Kyrle J, et al
    LDR brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse.
    BJU Int. 2018 Apr 1. doi: 10.1111/bju.14223.
    PubMed     Abstract available


  206. BANDINI M, Marchioni M, Pompe RS, Tian Z, et al
    First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy.
    BJU Int. 2018;121:592-599.
    PubMed     Abstract available


    March 2018
  207. VATANDOUST S, Kichenadasse G, O'Callaghan M, Vincent AD, et al
    Localized prostate cancer in elderly men aged 80-89, findings from a population-based registry.
    BJU Int. 2018 Mar 30. doi: 10.1111/bju.14228.
    PubMed     Abstract available


  208. ANSMANN L, Winter N, Ernstmann N, Heidenreich A, et al
    Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW).
    BJU Int. 2018 Mar 30. doi: 10.1111/bju.14215.
    PubMed     Abstract available


  209. STATTIN P, Sandin F, Loeb S, Robinson D, et al
    Public online reporting from a nationwide population-based clinical prostate cancer register.
    BJU Int. 2018 Mar 25. doi: 10.1111/bju.14213.
    PubMed     Abstract available


  210. CHEN R, Dong X, Gleave M
    Molecular Model for Neuroendocrine Prostate Cancer Progression.
    BJU Int. 2018 Mar 22. doi: 10.1111/bju.14207.
    PubMed     Abstract available


  211. AUBERTIN K, Trinh VQ, Jermyn M, Baksic P, et al
    Mesoscopic characterization of prostate cancer using Raman spectroscopy: Potential for diagnostics and therapeutics.
    BJU Int. 2018 Mar 15. doi: 10.1111/bju.14199.
    PubMed     Abstract available


  212. RUSSO GI, Bier S, Hennenlotter J, Beger G, et al
    Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer.
    BJU Int. 2018 Mar 15. doi: 10.1111/bju.14200.
    PubMed     Abstract available


  213. VIDAL AC, Howard LE, de Hoedt A, Kane CJ, et al
    Obese Castration-Resistant Prostate Cancer Patients may be at a lower risk of all-cause mortality: Results from the SEARCH Database.
    BJU Int. 2018 Mar 9. doi: 10.1111/bju.14193.
    PubMed     Abstract available


  214. CHAO M, Ho H, Chan Y, Tan A, et al
    Prospective analysis of hydrogel spacer for prostate cancer patients undergoing radiotherapy.
    BJU Int. 2018 Mar 9. doi: 10.1111/bju.14192.
    PubMed     Abstract available


  215. COUTURE F, Tholomier C, Zorn KC
    Prostate cancer biochemical recurrence after salvage radiotherapy: first look into risk stratification and prognosis.
    BJU Int. 2018;121:320-321.
    PubMed    


  216. GHANEM S, Namdarian B, Challacombe B
    To drain or not to drain after robot-assisted radical prostatectomy? That is the question.
    BJU Int. 2018;121:321-322.
    PubMed    


  217. PALAYAPALAYAM GANAPATHI H, Onol F, Rogers T, Patel V, et al
    Nerve wrapping with biomaterials during radical prostatectomy to improve potency recovery.
    BJU Int. 2018;121:322-323.
    PubMed    


  218. SATHIANATHEN NJ, Christidis D, Konety BR, Lawrentschuk NL, et al
    Magnetic resonance imaging cognitive fusion biopsy - is near enough good enough?
    BJU Int. 2018;121:324-326.
    PubMed    


  219. PATEL VR, Sandri M, Grasso AAC, De Lorenzis E, et al
    A novel tool for predicting extracapsular extension during graded partial nerve sparing in radical prostatectomy.
    BJU Int. 2018;121:373-382.
    PubMed     Abstract available


  220. CHENAM A, Yuh B, Zhumkhawala A, Ruel N, et al
    Prospective randomised non-inferiority trial of pelvic drain placement vs no pelvic drain placement after robot-assisted radical prostatectomy.
    BJU Int. 2018;121:357-364.
    PubMed     Abstract available


  221. MAI Z, Xiao Y, Yan W, Zhou Y, et al
    Comparison of lesions detected and undetected by template-guided transperineal saturation prostate biopsy.
    BJU Int. 2018;121:415-420.
    PubMed     Abstract available


  222. PORPIGLIA F, Bertolo R, Fiori C, Manfredi M, et al
    Chitosan membranes applied on the prostatic neurovascular bundles after nerve-sparing robot-assisted radical prostatectomy: a phase II study.
    BJU Int. 2018;121:472-478.
    PubMed     Abstract available


    February 2018
  223. NASSAR ZD, Aref AT, Miladinovic D, Mah CY, et al
    Peri-Prostatic Adipose Tissue: The metabolic microenvironment of prostate cancer.
    BJU Int. 2018 Feb 20. doi: 10.1111/bju.14173.
    PubMed     Abstract available


  224. ALTOK M, Babaian K, Achim MF, Achim GC, et al
    Surgeon-Led Prostate Cancer Lymph Node Staging: Pathologic Outcomes Stratified by Robot-Assisted Dissection Templates and Patient Selection.
    BJU Int. 2018 Feb 15. doi: 10.1111/bju.14164.
    PubMed     Abstract available


  225. BOLTON EM, Lynch TH
    Are all gonadotropin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.
    BJU Int. 2018 Feb 13. doi: 10.1111/bju.14168.
    PubMed     Abstract available


  226. THURTLE D, Barrett T, Thankappan-Nair V, Koo B, et al
    Progression and treatment rates using an active surveillance protocol incorporating image guided baseline biopsies and multi-parametric MRI monitoring for men with favourable risk prostate cancer.
    BJU Int. 2018 Feb 13. doi: 10.1111/bju.14166.
    PubMed     Abstract available


  227. SOORIAKUMARAN P
    Surgery for oligometastatic prostate cancer: ready for prime time?
    BJU Int. 2018 Feb 12. doi: 10.1111/bju.14038.
    PubMed    


  228. WALLIS CJD, Satkunasivam R, Bhindi B
    Selecting patients for prostate cancer treatment: the role of comorbidity.
    BJU Int. 2018;121:164-165.
    PubMed    


  229. SOLIGO M, Sharma V, Karnes RJ
    Is it time for a more 'proactive' approach to metastatic prostate cancer?
    BJU Int. 2018;121:167-168.
    PubMed    


  230. BARNETT CL, Davenport MS, Montgomery JS, Wei JT, et al
    Cost-Effectiveness of Magnetic Resonance Imaging and Targeted Fusion Biopsy for Early Detection of Prostate Cancer.
    BJU Int. 2018 Feb 1. doi: 10.1111/bju.14151.
    PubMed     Abstract available


  231. GILBERT DC, Duong T, Sydes M, Bara A, et al
    Transdermal Oestradiol as a method of androgen suppression for Prostate Cancer within the STAMPEDE Trial Platform.
    BJU Int. 2018 Feb 1. doi: 10.1111/bju.14153.
    PubMed     Abstract available


  232. SONPAVDE G, Huang A, Wang L, Baser O, et al
    Taxane chemotherapy versus anti-androgen agents as first-line therapy for metastatic castration-resistant prostate cancer.
    BJU Int. 2018 Feb 1. doi: 10.1111/bju.14152.
    PubMed     Abstract available


  233. HEIDENREICH A, Pfister D
    Even 'low-dose' cabazitaxel requires careful and meticulous patient selection.
    BJU Int. 2018;121:163-164.
    PubMed    


  234. KENIGSBERG AP, Tamada T, Rosenkrantz AB, Llukani E, et al
    Multiparametric magnetic resonance imaging identifies significant apical prostate cancers.
    BJU Int. 2018;121:239-243.
    PubMed     Abstract available


  235. AUFFENBERG GB, Qi J, Gao Y, Miller DC, et al
    Evaluation of a needle disinfectant technique to reduce infection-related hospitalisation after transrectal prostate biopsy.
    BJU Int. 2018;121:232-238.
    PubMed     Abstract available


    January 2018
  236. RUTLEDGE AB, McLeod N, Mehan N, Regan TW, et al
    A clinician-centred program for behaviour change in the optimal use of staging investigations for newly diagnosed prostate cancer.
    BJU Int. 2018 Jan 23. doi: 10.1111/bju.14144.
    PubMed     Abstract available


  237. ABDEL-RAHMAN O, Cheung WY
    External Validation Of The Prostascore Model Among Metastatic Hormone-Sensitive Prostate Cancer Patients Recruited In The CHAARTED Study.
    BJU Int. 2018 Jan 23. doi: 10.1111/bju.14138.
    PubMed     Abstract available


  238. LAZAREV S, Thompson MR, Stone NN, Stock RG, et al
    Low-Dose-Rate Brachytherapy for Prostate Cancer: Outcomes Beyond 10 Years of Follow-Up.
    BJU Int. 2018 Jan 10. doi: 10.1111/bju.14122.
    PubMed     Abstract available


  239. SCHLUSSEL MARKOVIC E, Buckstein M, Stone NN, Stock RG, et al
    Outcomes and Toxicities in Intermediate-Risk Prostate Cancer Patients Treated with Brachytherapy Alone or Brachytherapy and Supplemental External Beam Radiation Therapy.
    BJU Int. 2018 Jan 10. doi: 10.1111/bju.14128.
    PubMed     Abstract available


  240. FLETCHER SA, Berg S, Trinh QD
    The new frontier of prostate biopsy: determining the role of image-guidance in moving the needle.
    BJU Int. 2018;121:4-5.
    PubMed    


  241. STONE N
    Low dose rate prostate brachytherapy in younger men.
    BJU Int. 2018;121:2.
    PubMed    


  242. BORKOWETZ A, Hadaschik B, Platzek I, Toma M, et al
    Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-naive patients.
    BJU Int. 2018;121:53-60.
    PubMed     Abstract available


  243. SHIN T, Smyth TB, Ukimura O, Ahmadi N, et al
    Diagnostic accuracy of a five-point Likert scoring system for magnetic resonance imaging (MRI) evaluated according to results of MRI/ultrasonography image-fusion targeted biopsy of the prostate.
    BJU Int. 2018;121:77-83.
    PubMed     Abstract available


  244. SU J, Zhu Q, Yuan L, Zhang Y, et al
    Transumbilical laparoendoscopic single-site radical prostatectomy and cystectomy with the aid of a transurethral port: a feasibility study.
    BJU Int. 2018;121:111-118.
    PubMed     Abstract available


    December 2017
  245. NANTON V, Appleton R, Loew J, Ahmed N, et al
    Men don't talk about their health, but will they CHAT? The potential of online holistic needs assessment in prostate cancer.
    BJU Int. 2017 Dec 27. doi: 10.1111/bju.14114.
    PubMed     Abstract available


  246. BRUINSMA SM, Zhang L, Roobol MJ, Bangma CH, et al
    The Movember Foundation's GAP3 cohort: A profile of the largest global prostate cancer active surveillance database to date.
    BJU Int. 2017 Dec 15. doi: 10.1111/bju.14106.
    PubMed     Abstract available


  247. VOSS J, Pal R, Ahmed S, Hannah M, et al
    Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer.
    BJU Int. 2017 Dec 14. doi: 10.1111/bju.14100.
    PubMed     Abstract available


  248. DRUSKIN SC, Tosoian JJ, Young A, Collica S, et al
    Incorporating Prostate Health Index Density, MRI, and Prior Negative Biopsy Status to Improve the Detection of Clinically Significant Prostate Cancer.
    BJU Int. 2017 Dec 12. doi: 10.1111/bju.14098.
    PubMed     Abstract available


  249. POON DM, Chan CK, Chan TW, Cheung FY, et al
    Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.
    BJU Int. 2017 Dec 6. doi: 10.1111/bju.14091.
    PubMed     Abstract available


  250. PORPIGLIA F, De Luca S
    Prostate cancer biomarkers: new scenarios in the multi-parametric magnetic resonance imaging era.
    BJU Int. 2017;120:745-746.
    PubMed    


  251. BULTIJNCK R, Van de Caveye I, Rammant E, Everaert S, et al
    Clinical Pathway improves Implementation of Evidence-based Strategies for the management of Androgen Deprivation Therapy-induced side effects in Prostate Cancer Patients.
    BJU Int. 2017 Dec 1. doi: 10.1111/bju.14086.
    PubMed     Abstract available


  252. BJURLIN MA, Taneja SS
    Novel risk stratification nomograms for counseling patients on the need for prostate biopsy.
    BJU Int. 2017;120:746-747.
    PubMed    


  253. DASGUPTA P
    NICE guidance and the BJUI.
    BJU Int. 2017;120:743.
    PubMed    


    November 2017
  254. KIRK PS, Borza T, Shahinian VB, Caram MEV, et al
    The implications of baseline bone health assessment at initiation of androgen deprivation therapy for prostate cancer.
    BJU Int. 2017 Nov 10. doi: 10.1111/bju.14075.
    PubMed     Abstract available


  255. SIRIWARDANA A, Thompson J, van Leeuwen PJ, Doig S, et al
    Initial multicentre experience of 68 gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited.
    BJU Int. 2017;120:673-681.
    PubMed     Abstract available


  256. BOEHM K, Leyh-Bannurah SR, Rosenbaum C, Brandi LS, et al
    Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy.
    BJU Int. 2017;120:666-672.
    PubMed     Abstract available


  257. HANSEN NL, Kesch C, Barrett T, Koo B, et al
    Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy.
    BJU Int. 2017;120:631-638.
    PubMed     Abstract available


  258. YAXLEY AJ, Yaxley JW, Thangasamy IA, Ballard E, et al
    Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions.
    BJU Int. 2017;120 Suppl 3:43-50.
    PubMed     Abstract available


  259. KINNEAR N, Smith R, Hennessey DB, Bolton D, et al
    Implementation rates of uro-oncology multidisciplinary meeting decisions.
    BJU Int. 2017;120 Suppl 3:15-20.
    PubMed     Abstract available


  260. LOEB S
    Educational intervention in prostate cancer.
    BJU Int. 2017;120.
    PubMed    


  261. CHALFIN HJ, Pienta KJ, Gorin MA
    Selection-free method reveals phenotypic diversity among prostate cancer circulating tumour cells.
    BJU Int. 2017;120.
    PubMed    


  262. STRATTON K
    Cystectomy for cT4 prostate cancer: the most radical treatment.
    BJU Int. 2017;120.
    PubMed    


  263. EPSTEIN JI
    Central pathology review of radical prostatectomy specimens does make a difference not only with grade.
    BJU Int. 2017;120.
    PubMed    


    October 2017
  264. GANDAGLIA G, Zaffuto E, Fossati N, Bandini M, et al
    Identifying the candidate for super extended staging pelvic lymph node dissection among patients with high-risk prostate cancer.
    BJU Int. 2017 Oct 24. doi: 10.1111/bju.14066.
    PubMed     Abstract available


  265. ILIC D, Evans SM, Allan CA, Jung JH, et al
    Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer: a Cochrane systematic review.
    BJU Int. 2017 Oct 24. doi: 10.1111/bju.14062.
    PubMed     Abstract available


  266. HANSEN NL, Barrett T, Kesch C, Pepdjonovic L, et al
    Multicentre evaluation of Magnetic Resonance Imaging supported transperineal prostate biopsy in biopsy-naive men with suspicion of prostate cancer.
    BJU Int. 2017 Oct 11. doi: 10.1111/bju.14049.
    PubMed     Abstract available


  267. KLAASSEN Z, Murphy DG
    STAMPEDE-ing Towards Androgen Biosynthesis Inhibition for Treatment of High-Risk Hormone-Naive Prostate Cancer: Changing the LATITUDE.
    BJU Int. 2017 Oct 9. doi: 10.1111/bju.14050.
    PubMed     Abstract available


  268. FRADET V, Toren P, Nguile-Makao M, Lodde M, et al
    Prognostic value of urinary PCA3 during active surveillance of low-risk prostate cancer in patients receiving 5alpha-reductase inhibitors.
    BJU Int. 2017 Oct 3. doi: 10.1111/bju.14041.
    PubMed     Abstract available


  269. HAMMARSTEN J
    Anomalous observation with regard to prostate cancer in cancer research.
    BJU Int. 2017;120:456-457.
    PubMed    


  270. ALBERTS AR, Roobol MJ, Drost FH, van Leenders GJ, et al
    Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    BJU Int. 2017;120:511-519.
    PubMed     Abstract available


  271. LLUKANI E, Lepor H
    Aetiology and management of earlier vs later biochemical recurrence after retropubic radical prostatectomy.
    BJU Int. 2017;120:505-510.
    PubMed     Abstract available


  272. ZHAO S, Xia M, Tang J, Yan Y, et al
    Actual lowering effect of metabolic syndrome on serum prostate-specific antigen levels is partly concealed by enlarged prostate: results from a large-scale population-based study.
    BJU Int. 2017;120:482-489.
    PubMed     Abstract available


  273. LOEB S, Stork B, Gold HT, Stout NK, et al
    Tweet this: how advocacy for breast and prostate cancers stacks up on social media.
    BJU Int. 2017;120:461-463.
    PubMed    


    September 2017
  274. VAN STAM MA, van der Poel HG, van der Voort van Zyp JRN, Tillier CN, et al
    The accuracy of patients' perceptions of the risks associated with localized prostate cancer treatments.
    BJU Int. 2017 Sep 28. doi: 10.1111/bju.14034.
    PubMed     Abstract available


  275. BLANCHARD P, Davis JW, Frank SJ, Kim J, et al
    Quality of life following brachytherapy or bilateral nerve sparing robotic prostatectomy for prostate cancer: a prospective cohort.
    BJU Int. 2017 Sep 20. doi: 10.1111/bju.14021.
    PubMed     Abstract available


  276. RULACH R, McKay S, Neilson S, White L, et al
    Real World Uptake, Safety Profile and Outcomes of Docetaxel in Newly Diagnosed Metastatic Prostate Cancer.
    BJU Int. 2017 Sep 20. doi: 10.1111/bju.14025.
    PubMed     Abstract available


  277. BOSCO C, Wong C, Garmo H, Crawley D, et al
    Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.
    BJU Int. 2017 Sep 20. doi: 10.1111/bju.14023.
    PubMed     Abstract available


  278. MARRA G, Dalmasso E, Angello M, Munegato S, et al
    Prostate Cancer Treatment in Renal Transplant Recipients: A Systematic Review.
    BJU Int. 2017 Sep 18. doi: 10.1111/bju.14018.
    PubMed     Abstract available


  279. POON Y, Pechlivanoglou P, Alibhai SMH, Naimark D, et al
    Systematic Review and Network Meta-Analysis on the Relative Efficacy of Osteoporotic Medications: Men with Prostate Cancer on Continuous Androgen Deprivation Therapy to Reduce Risk of Fragility Fractures.
    BJU Int. 2017 Sep 18. doi: 10.1111/bju.14015.
    PubMed     Abstract available


  280. TAAFFE DR, Buffart LM, Newton RU, Spry N, et al
    Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
    BJU Int. 2017 Sep 5. doi: 10.1111/bju.14008.
    PubMed     Abstract available


  281. LAWRENTSCHUK N, Corfield JM, Scott A
    Is choline-based PET imaging still relevant in recurrent prostate cancer?
    BJU Int. 2017;120:303-304.
    PubMed    


  282. STEURER S, Rico SD, Simon R, Minner S, et al
    High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens.
    BJU Int. 2017;120:365-376.
    PubMed     Abstract available


  283. JACKSON WC, Desai NB, Abugharib AE, Tumati V, et al
    Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study.
    BJU Int. 2017;120:351-357.
    PubMed     Abstract available


  284. KIM PJ, Park JY, Kim HG, Cho YM, et al
    Dishevelled segment polarity protein 3 (DVL3): a novel and easily applicable recurrence predictor in localised prostate adenocarcinoma.
    BJU Int. 2017;120:343-350.
    PubMed     Abstract available


  285. SUARDI N, Montorsi F
    Salvage lymph node dissection: if yes, robotics?
    BJU Int. 2017;120:304-305.
    PubMed    


  286. FICARRA V, Novara G, Dasgupta P
    Robot-assisted vs open radical prostatectomy: the day after.
    BJU Int. 2017;120:308-309.
    PubMed    


    August 2017
  287. SCHELTEMA MJ, van den Bos W, Siriwardana AR, Kalsbeek AMF, et al
    Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
    BJU Int. 2017 Aug 21. doi: 10.1111/bju.13991.
    PubMed     Abstract available


  288. JANG WS, Kim MS, Jeong WS, Chang KD, et al
    Does robot-assisted radical prostatectomy benefit prostate cancer patients with bone oligometastases?
    BJU Int. 2017 Aug 21. doi: 10.1111/bju.13992.
    PubMed     Abstract available


  289. THOMPSON A, Beresford MJ, Sarmah P, Jefferies ER, et al
    Management of metastatic prostate cancer in the elderly: identifying fitness for chemotherapy in the post STAMPEDE world.
    BJU Int. 2017 Aug 19. doi: 10.1111/bju.13990.
    PubMed     Abstract available


  290. VAN DEN BOS W, Scheltema MJ, Siriwardana AR, Kalsbeek AMF, et al
    Focal irreversible electroporation as primary treatment for localized prostate cancer.
    BJU Int. 2017 Aug 10. doi: 10.1111/bju.13983.
    PubMed     Abstract available


  291. THALMANN GN, Nguyen DP
    Sentinel nodes in prostate cancer- are we chasing a ghost?
    BJU Int. 2017;120:161-162.
    PubMed    



  292. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated: (c) NICE (2016) Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.
    BJU Int. 2017;120:168-184.
    PubMed    


  293. GORIN MA, Pomper MG, Pienta KJ, Rowe SP, et al
    Defining the clinical utility of PSMA-targeted PET imaging of prostate cancer.
    BJU Int. 2017;120:160-161.
    PubMed    


  294. PAVLOVICH CP, Rocco B, Druskin SC, Davis JW, et al
    Urinary continence recovery after radical prostatectomy - anatomical/reconstructive and nerve-sparing techniques to improve outcomes.
    BJU Int. 2017;120:185-196.
    PubMed     Abstract available


  295. KADONO Y, Machioka K, Nakashima K, Iijima M, et al
    Changes in penile length after radical prostatectomy: investigation of the underlying anatomical mechanism.
    BJU Int. 2017;120:293-299.
    PubMed     Abstract available


  296. SUJENTHIRAN A, Charman SC, Parry M, Nossiter J, et al
    Quantifying severe urinary complications after radical prostatectomy: the development and validation of a surgical performance indicator using hospital administrative data.
    BJU Int. 2017;120:219-225.
    PubMed     Abstract available



  297. Abstracts of the 18th Asia-Pacific Prostate Cancer Conference 2017, Australia, 30 August-02 September 2017.
    BJU Int. 2017;120 Suppl 1:5-23.
    PubMed    


  298. MCGRATH S, Christidis D, Clarebrough E, Ingle R, et al
    Transperineal prostate biopsy - tips for analgesia.
    BJU Int. 2017;120:164-167.
    PubMed    


    July 2017
  299. ONG WL, Foroudi F, Evans S, Millar J, et al
    Large institutional variations in androgen deprivation therapy utilization with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
    BJU Int. 2017 Jul 27. doi: 10.1111/bju.13969.
    PubMed     Abstract available


  300. BASOURAKOS SP, Davis JW, Chapin BF, Ward JF, et al
    Baseline and Longitudinal Plasma Caveolin-1 Level as a Biomarker in Active Surveillance for Early Stage Prostate Cancer.
    BJU Int. 2017 Jul 15. doi: 10.1111/bju.13963.
    PubMed     Abstract available


  301. DESS RT, Hartman HE, Aghdam N, Jackson WC, et al
    Erectile Function after Stereotactic Body Radiotherapy for Localized Prostate Cancer.
    BJU Int. 2017 Jul 15. doi: 10.1111/bju.13962.
    PubMed     Abstract available


  302. LANGLEY SEM, Soares R, Uribe J, Uribe-Lewis S, et al
    Long-term oncological outcomes and toxicity in 597 men </=60 years of age at time of low dose rate brachytherapy for localised prostate cancer.
    BJU Int. 2017 Jul 3. doi: 10.1111/bju.13946.
    PubMed     Abstract available


  303. BASOURAKOS SP, Hoffman K, Kim J
    Active surveillance in prostate cancer: new efforts, new voices, new hope.
    BJU Int. 2017;120:4-5.
    PubMed    


  304. SAYYID R, Perlis N, Ahmad A, Evans A, et al
    Development and external validation of a biopsy-derived nomogram to predict risk of ipsilateral extraprostatic extension.
    BJU Int. 2017;120:76-82.
    PubMed     Abstract available


  305. MOSCHINI M, Sharma V, Gandaglia G, Dell'Oglio P, et al
    Long-term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy.
    BJU Int. 2017;120:69-75.
    PubMed     Abstract available


  306. MAMAWALA MM, Rao K, Landis P, Epstein JI, et al
    Risk prediction tool for grade re-classification in men with favourable-risk prostate cancer on active surveillance.
    BJU Int. 2017;120:25-31.
    PubMed     Abstract available


    June 2017
  307. DE BRUYCKER A, Lambert B, Claeys T, Delrue L, et al
    Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy.
    BJU Int. 2017 Jun 24. doi: 10.1111/bju.13938.
    PubMed     Abstract available


  308. SOORIAKUMARAN P
    Testing Radical prostatectomy in men with prostate cancer and oligoMetastases to the bone: a randomised controlled feasibility trial.
    BJU Int. 2017 Jun 5. doi: 10.1111/bju.13925.
    PubMed     Abstract available


  309. TUMATI V, Jackson WC, Abugharib AE, Raj G, et al
    Natural History of 'Second' Biochemical Failure Following Salvage Radiation Therapy for Prostate Cancer: A Multi-Institution Study.
    BJU Int. 2017 Jun 5. doi: 10.1111/bju.13926.
    PubMed     Abstract available


  310. VILLERS A, Flamand V, Arquimedes RC, Puech P, et al
    Robot-assisted partial prostatectomy for anterior prostate cancer: a step-by-step guide.
    BJU Int. 2017;119:968-974.
    PubMed     Abstract available


  311. DIOLOMBI ML, Epstein JI
    Metastatic potential to regional lymph nodes with Gleason score </=7, including tertiary pattern 5, at radical prostatectomy.
    BJU Int. 2017;119:872-878.
    PubMed     Abstract available


  312. CAVALLO JA, Tewari AK
    Somatic-autonomic neurorrhaphy for erectile function restoration after radical prostatectomy.
    BJU Int. 2017;119:816-818.
    PubMed    


    May 2017
  313. HEDDEN L, Wassersug R, Mahovlich S, Pollock P, et al
    Evaluating an educational intervention to alleviate distress amongst men with newly diagnosed prostate cancer and their partners.
    BJU Int. 2017 May 17. doi: 10.1111/bju.13885.
    PubMed     Abstract available


  314. CHIU PKF, Alberts AR, Venderbos LDF, Bangma CH, et al
    Additional benefit of using a risk based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    BJU Int. 2017 May 12. doi: 10.1111/bju.13913.
    PubMed     Abstract available


  315. TOSOIAN JT, Chappidi MR, Bishoff JT, Freedland SJ, et al
    Prognostic Utility of Biopsy-Derived Cell Cycle Progression Score in Patients with NCCN Low-Risk Prostate Cancer Undergoing Radical Prostatectomy: Implications for Treatment Guidance.
    BJU Int. 2017 May 8. doi: 10.1111/bju.13911.
    PubMed     Abstract available


  316. GREIMAN AK, Rosoff JS, Prasad SM
    Association of Human Development Index with global bladder, kidney, prostate and testis cancer incidence and mortality.
    BJU Int. 2017 May 8. doi: 10.1111/bju.13875.
    PubMed     Abstract available


  317. ZUMSTEG ZS, Zelefsky MJ, Woo KM, Spratt DE, et al
    Unification of favorable intermediate, unfavorable intermediate, and very high risk-stratification criteria for prostate cancer.
    BJU Int. 2017 May 2. doi: 10.1111/bju.13903.
    PubMed     Abstract available


  318. GANDAGLIA G, Fossati N, Dell'Oglio P, Montorsi F, et al
    Is there a role for pure clinical prediction models in prostate cancer in the contemporary era?
    BJU Int. 2017;119:652-653.
    PubMed    


  319. TOSOIAN JJ, Chappidi M, Feng Z, Humphreys EB, et al
    Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
    BJU Int. 2017;119:676-683.
    PubMed     Abstract available


  320. FRYDENBERG M
    Reliability of negative multiparametric MRI of the prostate: can we avoid the biopsy? Not yet!
    BJU Int. 2017;119:E9-E10.
    PubMed    


    April 2017
  321. PROTOPAPA E, van der Meulen J, Moore CM, Smith SC, et al
    Patient Reported Outcome (PRO) questionnaires for men who have radical surgery for prostate cancer: a conceptual review of existing instruments.
    BJU Int. 2017 Apr 24. doi: 10.1111/bju.13896.
    PubMed     Abstract available


  322. PARSONS JK, Pierce JP, Mohler J, Paskett E, et al
    The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): Recruitment Feasibility and Baseline Demographics of a Randomized Trial of Diet in Men on Active Surveillance for Prostate Cancer.
    BJU Int. 2017 Apr 24. doi: 10.1111/bju.13890.
    PubMed     Abstract available


  323. CHIEN GW, Slezak JM, Harrison TN, Jung H, et al
    Health-related quality of life outcomes from a contemporary prostate cancer registry in a large diverse population.
    BJU Int. 2017 Apr 19. doi: 10.1111/bju.13843.
    PubMed     Abstract available


  324. CRAWLEY D, Garmo H, Rudman S, Stattin P, et al
    Association between Type 2 diabetes, curative treatment and survival in men with intermediate and high risk localised prostate cancer.
    BJU Int. 2017 Apr 18. doi: 10.1111/bju.13880.
    PubMed     Abstract available


  325. VIOLET JA, Hofman MS
    Prostate specific membrane antigen (PSMA) from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer.
    BJU Int. 2017 Apr 5. doi: 10.1111/bju.13871.
    PubMed     Abstract available


  326. EMBERTON M
    An end to the phenomenon of 'upgrading' in early prostate cancer?
    BJU Int. 2017;119:506-507.
    PubMed    


  327. BAUER RM, Grabbert MT, Klehr B, Gebhartl P, et al
    36-month data for the AdVance XP(R) male sling: results of a prospective multicentre study.
    BJU Int. 2017;119:626-630.
    PubMed     Abstract available


  328. DAVIS JW, MacLennan G
    The BJUI's clinical trials initiative.
    BJU Int. 2017;119:503.
    PubMed    


    March 2017
  329. TELANG JM, Lane BR, Cher ML, Miller DC, et al
    Prostate cancer, family history, and eligibility for active surveillance: A systematic review of the literature.
    BJU Int. 2017 Mar 29. doi: 10.1111/bju.13862.
    PubMed     Abstract available


  330. DIJKSTRA S, Govers TM, Hendriks RJ, Schalken JA, et al
    Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.
    BJU Int. 2017 Mar 29. doi: 10.1111/bju.13861.
    PubMed     Abstract available


  331. GROGAN J, Gupta R, Mahon KL, Stricker PD, et al
    Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in radical prostatectomy patients with long-term follow up.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13857.
    PubMed     Abstract available


  332. HOWARD LE, Moreira D, De Hoedt A, Aronson WJ, et al
    Cut-points for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13856.
    PubMed     Abstract available


  333. CLEMENT-ZHAO A, Auvray M, Aboudagga H, Blanc-Durand F, et al
    Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13855.
    PubMed     Abstract available


  334. MACLENNAN S, Williamson PR, Bekema H, Campbell M, et al
    A core outcome set for localised prostate cancer effectiveness trials.
    BJU Int. 2017 Mar 27. doi: 10.1111/bju.13854.
    PubMed     Abstract available


  335. KANDASWAMY GV, Bennett A, Narahari K, Hughes O, et al
    Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate risk localised prostate cancer - results from a large contemporaneous cohort.
    BJU Int. 2017 Mar 20. doi: 10.1111/bju.13850.
    PubMed     Abstract available


  336. BALL MW, Harris KT, Schwen ZR, Mullins JK, et al
    Pathological analysis of the prostatic anterior fat pad at radical prostatectomy: insights from a prospective series.
    BJU Int. 2017;119:444-448.
    PubMed     Abstract available


  337. GETTMAN MT
    Rethinking cancer surveillance with shared-care models and survivorship plans: the time is now!
    BJU Int. 2017;119:360-361.
    PubMed    


    February 2017
  338. FICARRA V, Crestani A, Rossanese M, Palumbo V, et al
    Urethral-fixation technique improves early urinary continence recovery in patients who undergo retropubic radical prostatectomy.
    BJU Int. 2017;119:245-253.
    PubMed     Abstract available


  339. MATHIEU R, Lucca I, Vartolomei MD, Mbeutcha A, et al
    Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study.
    BJU Int. 2017;119:234-238.
    PubMed     Abstract available


  340. WASHINO S, Okochi T, Saito K, Konishi T, et al
    Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naive patients.
    BJU Int. 2017;119:225-233.
    PubMed     Abstract available


    January 2017
  341. SANTOK GD, Abdel Raheem A, Kim LH, Chang K, et al
    Perioperative and short-term outcomes of Retzius-sparing robot-assisted laparoscopic radical prostatectomy stratified by gland size.
    BJU Int. 2017;119:135-141.
    PubMed     Abstract available


  342. ZARGAR H, van den Bergh R, Moon D, Lawrentschuk N, et al
    The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
    BJU Int. 2017;119:110-115.
    PubMed     Abstract available


  343. DANNEMAN D, Drevin L, Delahunt B, Samaratunga H, et al
    Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000-2012.
    BJU Int. 2017;119:50-56.
    PubMed     Abstract available


  344. PARK SY, Oh YT, Jung DC, Cho NH, et al
    Diffusion-weighted imaging predicts upgrading of Gleason score in biopsy-proven low grade prostate cancers.
    BJU Int. 2017;119:57-66.
    PubMed     Abstract available


  345. TOSOIAN JJ, Epstein JI
    Prognostic value of prostate biopsy grade: forever a product of sampling.
    BJU Int. 2017;119:5-7.
    PubMed    


  346. PERERA M, Katelaris N, Murphy DG, McGrath S, et al
    Prostate Imaging Reporting and Data System score of four or more: active surveillance no more.
    BJU Int. 2017;119:9-12.
    PubMed    


    October 2016
  347. MATARAZA JM, Gotwals P
    Recent advances in immuno-oncology and its application to urological cancers.
    BJU Int. 2016;118:506-14.
    PubMed     Abstract available


  348. DEVECI S, Gotto GT, Alex B, O'Brien K, et al
    A survey of patient expectations regarding sexual function following radical prostatectomy.
    BJU Int. 2016;118:641-5.
    PubMed     Abstract available


  349. WYSOCK JS, Mendhiratta N, Zattoni F, Meng X, et al
    Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results.
    BJU Int. 2016;118:515-20.
    PubMed     Abstract available


  350. MURRAY NP, Aedo S, Reyes E, Orellana N, et al
    Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
    BJU Int. 2016;118:556-62.
    PubMed     Abstract available


    June 2016
  351. ANDERSON CB, Tin AL, Sjoberg DD, Mulhall JP, et al
    Association between number of prostate biopsies and patient-reported functional outcomes after radical prostatectomy: implications for active surveillance protocols.
    BJU Int. 2016;117.
    PubMed     Abstract available


  352. DE NUNZIO C, Presicce F, Lombardo R, Cancrini F, et al
    Physical activity as a risk factor for prostate cancer diagnosis: a prospective biopsy cohort analysis.
    BJU Int. 2016;117.
    PubMed     Abstract available


  353. DINH KT, Mahal BA, Ziehr DR, Muralidhar V, et al
    Risk of prostate cancer mortality in men with a history of prior cancer.
    BJU Int. 2016;117.
    PubMed     Abstract available


  354. WATSON E, Shinkins B, Frith E, Neal D, et al
    Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up.
    BJU Int. 2016;117.
    PubMed     Abstract available


    June 2015
  355. PARK J, Cho SY, Jeong SH, Lee SB, et al
    Low testosterone level is an independent risk factor for high-grade prostate cancer detection via biopsy.
    BJU Int. 2015 Jun 18. doi: 10.1111/bju.13206.
    PubMed     Abstract available


    May 2015
  356. CARLSSON S, Drevin L, Loeb S, Widmark A, et al
    Population-based study of long-term functional outcomes after prostate cancer treatment.
    BJU Int. 2015 May 8. doi: 10.1111/bju.13179.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: